J Aalten1, J F M Wetzels, A J Hoitsma. 1. Department of Nephrology, Radboud University Nijmegen Medical Center, The Netherlands. j.aalten@nier.umcn.nl
Abstract
BACKGROUND: Cinacalcet is used for treating secondary hyperparathyroidism in dialysis patients, but it is currently unknown whether it can safely be continued immediately after renal transplantation. METHODS: We prospectively studied renal transplant recipients with secondary hyperparathyroidism who were receiving cinacalcet before transplantation and continued treatment afterwards (n = 29) at a dose of 30 mg/day. Cinacalcet dose was titrated to serum calcium. Patients were followed for 6 months. Incidence of hypercalcemia, serum calcium and intact PTH (iPTH) were analyzed. Tacrolimus levels, acute rejection rate and renal function were compared with an age and sex matched control group. RESULTS: In 16 patients hypercalcemia was observed after transplantation. Severe hypercalcemia (>= 2.87 mmol/l) (n = 4) and hypocalcemia (n = 2) were infrequent. No difference in acute rejection rate or renal function between the cinacalcet and the control group was found. There also was no clinically relevant influence of cinacalcet on tacrolimus levels. CONCLUSIONS: Our study shows that cinacalcet can safely be continued immediately after renal transplantation. Studies are needed to determine if continuation of cinacalcet is better than early withdrawal. Also, the optimum dose of cinacalcet and the long-term effects of cinacalcet after renal transplantation must be defined.
BACKGROUND:Cinacalcet is used for treating secondary hyperparathyroidism in dialysis patients, but it is currently unknown whether it can safely be continued immediately after renal transplantation. METHODS: We prospectively studied renal transplant recipients with secondary hyperparathyroidism who were receiving cinacalcet before transplantation and continued treatment afterwards (n = 29) at a dose of 30 mg/day. Cinacalcet dose was titrated to serum calcium. Patients were followed for 6 months. Incidence of hypercalcemia, serum calcium and intact PTH (iPTH) were analyzed. Tacrolimus levels, acute rejection rate and renal function were compared with an age and sex matched control group. RESULTS: In 16 patientshypercalcemia was observed after transplantation. Severe hypercalcemia (>= 2.87 mmol/l) (n = 4) and hypocalcemia (n = 2) were infrequent. No difference in acute rejection rate or renal function between the cinacalcet and the control group was found. There also was no clinically relevant influence of cinacalcet on tacrolimus levels. CONCLUSIONS: Our study shows that cinacalcet can safely be continued immediately after renal transplantation. Studies are needed to determine if continuation of cinacalcet is better than early withdrawal. Also, the optimum dose of cinacalcet and the long-term effects of cinacalcet after renal transplantation must be defined.
Authors: Myles Wolf; Matthew R Weir; Nelson Kopyt; Roslyn B Mannon; Jon Von Visger; Hongjie Deng; Susan Yue; Flavio Vincenti Journal: Transplantation Date: 2016-01 Impact factor: 4.939
Authors: R R Dulfer; E Y Koh; W Y van der Plas; A F Engelsman; E J M Nieveen van Dijkum; R A Pol; L Vogt; M H de Borst; S Kruijff; A Schepers; N M Appelman-Dijkstra; J I Rotmans; D A Hesselink; C H J van Eijck; E J Hoorn; T M van Ginhoven Journal: Langenbecks Arch Surg Date: 2019-02-07 Impact factor: 3.445